1. The Interface between Rheumatology and Dermatology: Why Rheumaderm?.- 2. Nature and Nurture in Systemic Lupus Erythematosus.- 3. Heritable Connective Tissue Disorders.- 4. Neonatal Lupus Erythematosus.- 5. Prognosis in Juvenile Arthritis.- 6. Scleroderma in Children.- 7. Localized Morphea in Children.- 8. Autoimmune Thyroid Disorders in Juvenile Chronic Arthritis and Systemic Lupus Erythematosus.- 9. Prevalence of IgM-, IgA- and IgG-Rheumatoid Factors in Seronegative Polyarticular Disease Compared to Pauciarticular ...
Read More
1. The Interface between Rheumatology and Dermatology: Why Rheumaderm?.- 2. Nature and Nurture in Systemic Lupus Erythematosus.- 3. Heritable Connective Tissue Disorders.- 4. Neonatal Lupus Erythematosus.- 5. Prognosis in Juvenile Arthritis.- 6. Scleroderma in Children.- 7. Localized Morphea in Children.- 8. Autoimmune Thyroid Disorders in Juvenile Chronic Arthritis and Systemic Lupus Erythematosus.- 9. Prevalence of IgM-, IgA- and IgG-Rheumatoid Factors in Seronegative Polyarticular Disease Compared to Pauciarticular Disease in Juvenile Chronic Arthritis as Measured by ELISA.- 10. Incidence and Outcome of Kawasaki Disease in Malta.- 11. Systemic Sclerosis: AClinical Overview.- 12. Scleroderma Overlap Syndromes.- 13. Raynaud's Phenomenon and Vascular Disease in Systemic Sclerosis.- 14. Linear Scleroderma en Coup de Sabre: Relationship with Progressive Facial Hemiatrophy (PFH).- 15. Scleroderma Profunda: Clinicopathological Studies.- 16. Early Diagnosis of Systemic Sclerosis.- 17. Cutaneous Necrotizing Vasculitis: Relation to Systemic Disease.- 18. Sj???gren's Syndrome: Autoimmune Epithelitis.- 19. Beh???et's Syndrome: The Cerrahpasa Experience H. Yazici and the Members of the Beh???et's Syndrome Research Centre.- 20. Autoantibodies in SLE: Disease Associations.- 21. Polymorphisms of the Xenobiotic-Metabolizing Enzymes CYP1A1 and NAT-2 in Systemic Sclerosis and Lupus Erythematosus.- 22. Elevated Soluble E-Selectin in Cutaneous Lupus Erythematosus.- 23. RNP Positivity in Maltese SLE Patients.- 24. Chilblain Lupus Erythematosus Is Associated with Antibodies to SSA/Ro.- 25. Male SLE Patients in Malta.- 26. Dermatomyositis: Diagnosis and Evaluation of Dermatomyositis, Polymyositis, Inclusion-Body Myositis.- 27. Dermatomyositis and Drugs.- 28. Dermatomyositis Associated with Malignancy: 12 Case Reports.- 29. Reactive Arthritis.- 30. Psoriatic Arthritis: Is Something Changing?.- 31. Incidence of Antiperinuclear Factor in Patients with Psoriatic Arthritis.- 32. Triggered Psoriasis.- 33. Pyridinium Crosslinks Excretion in Patients with Rheumatoid Arthritis: Correlation with Disease Activity and Glucocorticoid Treatment.- 34. Porphyria: From Sir Walter Raleigh to Molecular Biology.- 35. Photosensitivity and Joint Dysfunction.- 36. Role of Superantigens in Dermatology.- 37. Intravascular Lymphomatosis: A Report of Ten Patients with Central Nervous System Involvement and a Review of the Disease Process.- 38. Pemphigus and Diet: Have We Solved the Mystery of Fogo Selvagem?.- 39. The Treatment of Systemic Sclerosis.- 40. Enalapril (10 Mg/Day) in Systemic Sclerosis: One Year, Double Blind, Randomised Study (ESS-1): Echocardiographic Substudy-Three Months Follow-Up..- 41. Enalapril (10 Mg/Day) in Systemic Sclerosis: One Year, Double Blind, Randomised Study (ESS-1): ECG Exercise Testing-Three Months Follow-Up.- 42. Enalapril (10 Mg/Day) in Systemic Sclerosis: One Year, Double Blind, Randomised Study (ESS-1): Pulmonary Substudy-Effects of Three Month Treatment.- 43. Enalapril (10Mg/Day) in Systemic Sclerosis: One Year, Double Blind, Randomised Study (ESS-1): Electrocardiographic Substudy-Three Months Follow-Up, .- 44. Treatment of Generalized Morphea with Oral 1.25- Dihydroxyvitamin D3.- 45. Vasospasmolytic Therapy in Patients with SSC.- 46. Biomechanical Stimulation Therapy: A Novel Physiotherapy Method for Systemic Sclerosis.- 47. Reduced Skin Stiffness by Grenz Ray Treatment in Generalized Morphea.- 48. NSAIDs/Corticosteroids-Primum Non Nocere.- 49. Management Issues in Vasculitis.- 50. Sulphasalazine: An Alternative Drug for Second-Line Treatment of Juvenile Chronic Arthritis.- 51. Cyclosporin A and Retinoids in Psoriasis.- 52. Methotrexate.- 53. Azathioprine in Dermatological Practice: An Overview with Special Emphasis on Its Use in Non-Bullous Inflammatory Dermatoses.- 54. The Effect of Methylprednisolone Pulse Therapy in Polymyositis/ Dermatomyositis.- 55. Toxicity Profile of Methotrexate in Rheumatoid Arthritis: A Prel
Read Less
